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Delphine Fradin1 and Pierre Bougnères1,2*Abstract
Palmitic acid, or hexadecanoic acid, a 16-carbon saturated fatty acid (FA), accounts for approximately 38% of the
total circulating FA in lean or obese humans. In an article published in BMC Medicine, Hall et al. report that cultured
islets from healthy donors, when exposed to palmitate, undergo changes in CpG methylation that are associated
with modifications of expression in 290 genes. Their results provide a first look at the mechanisms used by the
endocrine pancreas of humans to keep a durable genomic imprint from their exposure to FA that can influence
gene expression and possibly cell phenotype in the long term. It is likely that such studies will help understand the
epigenetic response of β cells to a disturbed metabolic environment, especially one created by obesity.
Please see related article: http://www.biomedcentral.com/1741-7015/12/103
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In order to understand the findings of Hall et al. [1] one
would have to ask why would β cells keep an epigenetic
memory of prior exposure to fatty acids (FA)? The β
cells continuously receive and integrate multiple neuro-
secretory, endocrine and metabolic signals originating
mostly from the brain. Furthermore, they are also equipped
to sense the circulating concentration of energy substrates
such as glucose or FA produced by the liver and the
adipose tissue, respectively. In contrast to glucose, plasma
FA varies over a physiological ten-fold concentration range
in response to the whole spectrum of ‘fight-or-flight; activ-
ities that were common in the early times of Homo sapiens
during everyday life: strenuous or prolonged physical
activity [2], protracted fasting, fear, psychological stress
[3], cold exposure [4] and exercise in cold temperatures
[5]. In each of these situations, an almost immediate in-
crease in circulating FA up to approximately 2 mmol/L
is caused by β-adrenergic stimulation of adipose tissue
lipolysis. Lasting more than several hours, the increase in
FA is intended to provide readily oxidizable fuels to skeletal* Correspondence: pierre.bougneres@inserm.fr
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2014muscle and heart and spare glucose for concomitant brain
activity. Insulin secretion, a major player in this metabolic
response, decreases in response to the secreted catechol-
amines. This decrease contrasts with the increased insulin
secretion elicited by FA when they are infused alone, a
situation where β cell activity is not shut down by cate-
cholamines [6]. Palmitate is also increased in other cir-
cumstances of normal human physiology. The palmitate
level increases during pregnancy [7] (but does not flow
from mother to fetus) and during lactation. Birth is associ-
ated with massive palmitate release [8]. The human β cells
are thus accustomed to facing transient increases in palmi-
tate concentrations at times as part of normal life. It would
be tempting to speculate that since these events are more
than common, β cells would find little interest in keeping
memories of such short-lived elevations of FA.Fatty acids from obesity to type 2 diabetes
What early human β cells are not used to facing is a
protracted elevation of plasma FA that lasts for years
and is not associated with catecholamine secretion. This
is precisely the abnormal situation seen today in millions
of humans accumulating fat and becoming obese, in
whom mounting insulin resistance of the adipose tissue
begets FA release from fat stores. While this is occur-
ring, β cells synthesize and secrete abundant insulin,d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited.
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roles in the regulation of obesity-driven β-cell prolifera-
tion, including nutrients, insulin, incretins, hepatocyte
growth factor, and recently identified liver-derived secreted
factors. Much is still unknown about the proliferative path-
ways involved and the regulation of β-cell replication.
Nonetheless, as the duration and/or the severity of obesity
persist, beta cell mass decays and fails to compensate for
insulin resistance. This, together with β-cell dysfunction,
leads to the onset of type 2 diabetes (T2D). It is becoming
evident that elements in insulin signal-transduction path-
ways are key to regulating β cell growth. Increased β cell
apoptosis is an important factor contributing to β cell loss
and the onset of T2D [10].
What is the basis of β cell failure in T2D? FA have
long been shown to play a deleterious role, not only in
peripheral tissues [11], but also in the endocrine pan-
creas by affecting the tenuous balance between effective
pancreatic β-cell mass (through FA-induced lipotoxicity)
and insulin resistance (which increases circulating FA)
[12,13]. In contrast with the transient FA elevations oc-
curring in normal life, when β cells cease their secretory
activity, the sustained FA elevations of obese patients
[14] or of non-obese patients with T2D [15] become
part of the abnormal metabolic environment of β cells
that are chronically overstimulated by both insulin resist-
ance and hyperglycemia. At the β cell level this exposure
to high FA levels and high insulin secretory activity by the
pancreas represents a mismatch versus the evolution-
ary ‘natural’ situation.
The epigenetics of lipotoxicity to the
endocrine pancreas
To unravel the epigenetic effects of FA on β cells, Hall
et al. [1] studied changes in DNA methylation at CpG
nucleotides induced by 1 mmol/L palmitate in cultured
human pancreatic islets. They found that palmitate slightly
but significantly increased the level of DNA methylation
(44.9% versus 43.9%) in most regions of the genome, in-
cluding regions involved in the regulation of gene expres-
sion, such as promoters and CpG island shores or shelves,
not CpG islands themselves. To those who are not familiar
with the expression of methylation as a percentage, the
finding means that when exposed to palmitate, approxi-
mately 1% more of the cultured β cells became methylated
at the said genomic regions. Even if statistically significant,
this is nonetheless a minor change at the level of the whole
β cell population. More importantly, exposure to palmitate
changed the degree of DNA methylation of 46,977 sites at
the level of P <0.05, but none reached the significant false
discovery rate (FDR) q-value of 0.05. A total of 4,561 sites,
including 2,753 genes, displayed increased DNA methy-
lation due to palmitate treatment while only 129 sites
(94 genes) showed decreased DNA methylation. In thiscase, the changes in the islet cell population appear more
biologically important, since 46% to 84% of the cells
seemed to change their methylation status at specific
gene positions due to palmitate treatment. Palmitate
treatment of the cultured islets also altered glucose-
induced insulin secretion and modified the expression
of 1,860 genes that were down- or up-regulated. By in-
tegrating DNA methylation and gene expression data,
290 genes were found to show concomitant changes
both in expression and in CpG methylation, most showing
a decreased expression and an increase of DNA methyla-
tion. In cultured islets from donors affected by T2D, Hall
et al. [1] observed that 37 of the previously found 1,860
genes showed changes in expression versus non-diabetic
donors. Previous studies have already examined the effect
of palmitate on gene expression in human islets [16,17] and
it will be interesting to compare the results of the three
studies to determine how consistent they are.
Conclusions
The experimental system used by Hall et al. [1] to study
DNA methylation is not ideal. First, islets in culture
were 80% pure and were not composed uniquely of only
β cells. Thus, some of the observed DNA methylation
changes might reflect those occurring in non-β cells.
Secondly, these islets are isolated from their normal
physiological neuro-hormonal and metabolic signals.
This may explain why cultured islets secrete less insulin
when exposed to FA, while in vivo acute exposure of
islets to FA is associated with increased insulin secretion
in healthy subjects [6]. Thirdly, challenges exist also for
the study of islets from donors with T2D, that tend to be
much more sensitive to the isolation procedures com-
pared to islets cultured from non-diabetic controls
[17]. In addition, islets from donors with T2D may in-
clude cells from the inflammasome, possibly associated
with T2D [18]. Nevertheless, the observation of palmitate-
induced changes in DNA methylation paves the way for
further defining the metabolic memory of β cells at an
epigenetic level. In this respect, it would have been in-
teresting to know if Hall et al. [1] found differentially
methylated regions in islets from T2D donors versus
non-diabetic islets, or if they have compared their methy-
lation data with those collected by Dayeh et al. [19] and
Volkmar et al. [20] for a combined analysis, one that is
made mandatory by the small number of islet donors that
can be analyzed by any individual investigator. Indeed, then,
it is premature to comment further on the islet-expressed
genes whose methylation status is altered by palmitate.
Instead of highlighting imperfections of the cultured
islet system or lamenting the limited statistical relevance of
a small number of pancreatic samples from heterogeneous
groups of patients and controls, one should enjoy the pre-
liminary insights provided by the epigenetic analysis in the
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consider the limitations as opportunities for additional
research to clarify further the full extent of the clinical
relevance of the tantalizing data provided by Hall et al.
[1]. Clearly, this must be done since millions of modern
obese humans continuously expose their β cells to an
abnormal FA environment.
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